These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28159850)

  • 1. Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis.
    Elizondo RA; Karmonik C; Boone TB; Khavari R
    BMJ Open; 2017 Feb; 7(2):e013225. PubMed ID: 28159850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
    Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
    J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
    Leitner L; Walter M; Freund P; Mehnert U; Michels L; Kollias S; Kessler TM
    BMC Urol; 2014 Aug; 14():68. PubMed ID: 25132340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
    Álvares RA; Araújo ID; Sanches MD
    BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
    Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
    Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intradetrusor botulinum toxin A injections on serum and urinary concentrations of nerve growth factor and brain-derived neurotrophic factor in patients with multiple sclerosis and neurogenic detrusor overactivity.
    Philippova ES; Bazhenov IV; Ziryanov AV; Bazarny VV
    Neurourol Urodyn; 2021 Jan; 40(1):95-101. PubMed ID: 33034916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
    Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
    Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
    Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P
    Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.